Do COX-2 inhibitors reduce renal fibrosis?

Journal of Hypertension

Volumn 22, Issue 1, 2004, Pages 43-45

  Harding, Pamela ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ENALAPRIL; ETODOLAC; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; UNCLASSIFIED DRUG;

DISEASE MODEL; DRUG EFFECT; DRUG MECHANISM; DRUG SELECTIVITY; EDITORIAL; ENZYME INHIBITION; EXPERIMENT; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY TUBULE; LONG TERM CARE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; STAINING; SYSTOLIC BLOOD PRESSURE;

EID: 1442323647     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200401000-00010     Document Type: Editorial

References (22)

1. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994; 94:2504-2510.
2. Wang J-L, Cheng H-F, Zhang M-Z, McKanna JA, Harris RC. Selective increase of cyclooxygenase-2 expression in a model of renal ablation. Am J Physiol 1998; 275:F613-F622.
3. Hartner A, Goppelt-Struebe M, Hilgers KF. Coordinate expression of cyclooxygenase-2 and renin in the rat kidney in renovascular hypertension. Hypertension 1998; 31:201-205.
4. Chou SY, Cai H, Pai D, Mansour M, Huynh P. Regional expression of cyclooxygenase isoforms in the rat kidney in complete unilateral ureteral obstruction. J Urol 2003; 170:1403-1408.
5. Tomasoni S, Noris M, Zappella S, Gotti E, Casiraghi F, Bonazzola S, et al. Upregulation of renal and systemic cyclooxygenase-2 in patients with active lupus nephritis. J Am Soc Nephrol 1998; 9:1202-1212.
6. Komers R, Epstein M. Cyclooxygenase-2 expression and function in renal pathophysiology. J Hypertens 2002; 20 (suppl 6):S11-S15.
7. Sanchez PL, Salgado LM, Ferreri NR, Escalante B. Effect of cyclooxygenase-2 inhibition on renal function after renal ablation. Hypertension 1999; 34:848-853.
8. Miyajima A, Ito K, Asano T, Seta K, Ueda A, Hayakawa M. Does cyclooxygenase-2 inhibitor prevent renal tissue damage in unilateral ureteral obstruction? J Urol 2001; 166:1124-1129.
9. Blume C, Heise G, Muhlfeld A, Bach D, Schror K, Gerhardz CD, et al. Effect of flosulide, a selective cyclooxygenase-2 inhibitor, on passive Heymann nephritis in the rat. Kidney Int 1999; 56:1770-1778.
10. Schneider A, Harendza S, Zahner G, Jocks T, Wenzel U, Wolf G, et al. Cyclooxygenase metabolites mediate glomerular monocyte chemoattractant protein-1 formation and monocyte recruitment in experimental glomerulonephritis. Kidney Int 1999; 55:430-441.
11. Kitahara M, Eitner F, Ostendorf T, Kunter U, Janssen U, Westenfeld R, et al. Selective cyclooxygenase-2 inhibition impairs glomerular capillary healing in experimental glomerulonephritis. J Am Soc Nephrol 2002; 13:1261-1270.
12. Richter C-M, Godes M, Wagner C, Maser-Gluth C, Herzfeld S, Dorn M, et al. Chronic cyclooxygenase-2 inhibition does not alter blood pressure and kidney function in renovascular hypertensive rats. J Hypertens 2004; 22:191-198.
13. Harding P, Glass WF, Scherer S. COX-2 inhibition potentiates the antiproteinuric effect of enalapril in uninephrectomized SHR. Prostagland Leukotr Essent Fatty Acids 2003; 68:17-25.
14. Wang JL, Cheng HF, Shappell S, Harris RC. A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. Kidney Int 2000; 57:2334-2342.
15. Cheng HF, Wang CJ, Moeckel GW, Zhang MZ, McKanna JA, Harris RC. Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int 2002; 62:929-939.
16. Olson JL. Hypertension: essential and secondary forms. In: Jennette JC, Olson JL, Schwartz MM, Silva FG (editors): Heptinstall's pathology of the kidney, 5th edn. Philadelphia: Lippincott-Raven; 1998, pp. 943-1001.
17. Wang J-L, Cheng H-F, Harris RC. Cyclooxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension. Hypertension 1999; 34:96-101.
18. Harding P, Carretero OA, Beierwaltes WH. Chronic cyclooxygenase-2 inhibition blunts low sodium-stimulated renin without changing renal haemodynamics. J Hypertens 2000; 18:1107-1113.
19. Harris RC. Cyclooxygenase-2 and the kidney: functional and pathophysiological implications. J Hypertens 2002; 20 (suppl 6):S3-S9.
20. Mann B, Hartner A, Jensen BL, Hilgers KF, Hocherl K, Kramer BK, Kurtz A. Acute upregulation of COX-2 by renal artery stenosis. Am J Physiol Renal Physiol 2001; 280:F119-F125.
21. Tokuyama H, Hayashi K, Matsuda H, Kubota E, Honda M, Okubo K, et al. Distinct role of intrarenal cyclooxygenase-1/2 in chronic unilateral renal ischemia. Nephron 2002; 92:183-191.
22. Perazella MA. COX-2 selective inhibitors: analysis of the renal effects. Expert Opin Drug Saf 2002; 1:53-64.